ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

• Paolo Strati,
• Michelle A. Fanale,
• Yasuhiro Oki,
• Francesco Turturro,
• Luis E Fayad,
• Nancy L. Bartlett,
• Douglas E. Gladstone,
• Yvette L. Kasamon,
• Carol S. Portlock,
• Wyndham H. Wilson,
• Andre Goy,
• Anas Younes,
• Hun Ju Lee

Affiliations

Paolo Strati

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michelle A. Fanale

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;Seattle Genetics, WA

Yasuhiro Oki

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Francesco Turturro

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Luis E Fayad

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Nancy L. Bartlett

Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO

Douglas E. Gladstone

Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD

Yvette L. Kasamon

Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD

Carol S. Portlock

Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Wyndham H. Wilson

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Andre Goy

Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, NJ, USA

Anas Younes

Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Hun Ju Lee

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX